证券代码：300406 证券简称：九强生物 公告编号：2025-038 债券代码：123150 债券简称：九强转债 北京九强生物技术股份有限公司 关于九强转债恢复转股的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1、债券代码：123150 ；债券简称：九强转债 2、恢复转股时间：自 2025 年 5 月 6 日起恢复转股 北京九强生物技术股份有限公司（以下简称"公司"）因实施 2024年年度权益分派， 根据《北京九强生物技术股份有限公司创业板向不特定对象发行可转换公司债券募集 说明书》及相关规定，公司可转换公司债券（债券代码：123150 ；债券简称：九强转 债 ）自 2025 年 4 月 23 日至本次权益分派股权登记日（2025 年 4 月 30 日）止暂停转 股。具体内容详见公司于 2025 年 4 月 22 日披露的《关于实施权益分派期间九强转债 暂停转股的提示性公告》（公告编号：2025-033）。 根据规定，"九强转债" 将于本次权益分派股权登记日后的第一个交易日即 2025年 5 月 6 日起恢复转股，敬请 "九强转债 ...

Core Viewpoint - The article highlights the active cash dividend distribution by listed companies in the 2024 fiscal year, with a total of 3,669 companies announcing distribution plans, reflecting a strong emphasis on cash dividends encouraged by regulatory bodies [1][2]. Summary by Category Dividend Distribution - A total of 3,664 companies included cash dividends in their distribution plans for 2024, with a cumulative cash payout amounting to 1.64 trillion yuan [1]. - There are 346 companies that included stock transfers in their distribution plans for 2024 [1]. Key Dates for Investors - Important dates for investors focusing on dividends are the ex-dividend date and the record date. Currently, 119 companies have implemented their distribution plans, and investors should monitor whether these companies' stock prices can achieve a "filling rights" trend [1]. - For companies yet to implement their rights, investors may consider "抢权" (grabbing rights) before the record date, which is the last trading day for this dividend [1]. Notable Companies and Performance - Among the companies with a record date today, 9 out of 10 have a cash dividend of 1 yuan (tax included) or more per 10 shares. 雅艺科技 (Yayi Technology) has the highest payout of 5.00 yuan per 10 shares, followed by 九强生物 (Jiuqiang Biology) and 中润光学 (Zhongrun Optics) with payouts of 4.00 yuan and 3.50 yuan, respectively [1][2]. - The highest stock transfer ratio among the companies with a record date today is also from 雅艺科技, which has a distribution plan of 10 shares for every 3 shares transferred, along with a cash payout of 5 yuan [2]. - In terms of stock performance, 香山股份 (Xiangshan Co.) has seen the largest increase over the past five days, with a rise of 12.14%, followed by 三利谱 (Sanlipu) and 雅艺科技 (Yayi Technology) [2]. Summary of Upcoming Dividend Companies - A table lists companies with their respective cash payouts, stock transfer ratios, latest closing prices, and five-day price changes, indicating the financial health and market performance of these companies [2].

| 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-037 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 北京九强生物技术股份有限公司 关于"九强转债"预计触发转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： | 1、股票代码：300406 | 股票简称：九强生物 | | --- | --- | | 2、债券代码：123150 | 债券简称：九强转债 | 3、转股价格：当前为人民币 17.35 元/股 2025 年 5 月 6 日起为人民币 16.95 元/股 一、可转换公司债券基本情况 （一）可转换公司债券发行情况 经中国证券监督管理委员会《关于同意北京九强生物技术股份有限公司向不 特定对象发行可转换公司债券注册的批复》（证监许可〔2022〕1081 号）核准， 并经深圳证券交易所创业板上市委 2022 年第 13 次上市委员会审议会议审核通 过。北京九强生物技术股份有限公司于 2022 年 6 月 30 日公开发行可转换公司债 券（ ...

Core Viewpoint - The company reported a decline in revenue and net profit for Q1 2025, attributed to various market pressures and rising costs, while maintaining a strong gross margin due to an improved product mix [1][2]. Financial Performance - Q1 2025 revenue was 320 million yuan, a year-on-year decrease of 18.81% [1]. - The net profit attributable to shareholders was 83 million yuan, down 30.99% year-on-year [1]. - The non-recurring net profit was 82 million yuan, reflecting a 32.02% decline compared to the previous year [1]. - Gross margin for Q1 2025 was approximately 80.84%, an increase of about 3.98 percentage points year-on-year [1]. - The net profit margin for Q1 2025 was 26.13%, a decrease of 4.39 percentage points year-on-year [1]. Cost Structure - Sales expense ratio increased to 22.09%, up 4.38 percentage points year-on-year [1]. - Management expense ratio rose to 10.37%, an increase of 1.73 percentage points year-on-year [1]. - R&D expense ratio remained high at 13.45%, up 2.56 percentage points year-on-year [1]. - Financial expense ratio was 3.11%, an increase of 0.40 percentage points year-on-year [1]. Market Dynamics - The pathology business remains stable despite policy disruptions, while the biochemical sector may face short-term pressure due to ongoing national policies [2]. - The company is exploring AI integration in diagnostics and expanding its international presence, particularly in emerging markets [2]. Revenue and Profit Forecast - Projected revenues for 2025-2027 are 1.669 billion, 1.886 billion, and 2.129 billion yuan, with expected growth rates of 1%, 13%, and 13% respectively [3]. - Forecasted net profits for the same period are 553 million, 642 million, and 759 million yuan, with growth rates of 4%, 16%, and 18% respectively [3]. - The current stock price corresponds to a PE ratio of 15, 13, and 11 for 2025-2027, reflecting the company's strong growth potential in high-demand sectors [3].

Financial Performance - The company's revenue for Q1 2025 was ¥319,809,793.71, a decrease of 18.81% compared to ¥393,894,885.38 in the same period last year[5] - Net profit attributable to shareholders was ¥83,257,495.41, down 30.99% from ¥120,648,449.77 year-on-year[5] - Basic and diluted earnings per share decreased by 33.33% to ¥0.14 from ¥0.21 in the same period last year[5] - Operating profit for the current period was CNY 98,056,421.38, a decline of 31.9% from CNY 144,380,239.45 in the previous period[19] - The company reported a net profit of CNY 98,024,052.97 for the current period, down from CNY 142,407,950.93 in the previous period, reflecting a decrease of 30.9%[19] - Net profit for the current period is 83,572,615.29, a decrease of 30.6% compared to 120,219,484.04 in the previous period[20] - Total comprehensive income for the current period is 83,536,791.02, down 30.6% from 120,257,352.53 in the previous period[20] Cash Flow - The net cash flow from operating activities increased significantly by 304.24%, reaching ¥70,946,714.51 compared to ¥17,550,800.52 in the previous year[5] - Operating cash flow net amount increased significantly to 70,946,714.51 from 17,550,800.52, representing a growth of 303.5%[22] - Cash inflow from operating activities totaled 366,407,557.92, down 11.3% from 413,326,787.63 in the previous period[22] - Cash outflow from investing activities increased significantly to 137,138,675.41 from 39,384,851.07, indicating a rise of 248.5%[22] - Net cash flow from financing activities was negative at -3,247,940.80, compared to a positive 16,808,061.67 in the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,631,457,588.22, reflecting a 1.01% increase from ¥5,574,965,162.35 at the end of the previous year[5] - Total assets as of March 31, 2025, amounted to CNY 5,631,457,588.22, up from CNY 5,574,965,162.35 at the beginning of the period[18] - Total liabilities decreased to CNY 1,416,847,031.71 from CNY 1,442,165,213.96, indicating a reduction of 1.8%[18] - The company's short-term borrowings decreased by 63.18% to ¥38,982.51, primarily due to repayment of short-term loans[7] Operating Costs and Inventory - The company's operating costs decreased by 32.77% to ¥61,274,484.14 from ¥91,143,372.70 year-on-year, attributed to a decline in sales[7] - Total operating costs decreased to CNY 222,735,370.83, down 11.7% from CNY 252,157,863.84 in the previous period[19] - Inventory increased to CNY 231,884,150.32 from CNY 220,680,889.10, representing a rise of 5.4%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 15,231[9] - The company had 11,210,221 convertible bonds remaining with a total face value of CNY 1,121,022,100 as of the end of the first quarter of 2025[13] Investment Performance - The investment loss was reported at ¥-152,998.11, a significant decrease of 113.72% compared to a profit of ¥1,115,166.92 in the previous year[7] - Other comprehensive income attributable to the parent company showed a significant decline, with a net amount of -27,990.36 compared to 27,198.35 in the previous period[20]

九强生物（300406）公告，2025年第一季度营收为3.2亿元，同比下降18.81%；净利润为8325.75万元， 同比下降30.99%。 ...

| 证券代码：300406 | 证券简称：九强生物 公告编号：2025-034 | | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | 北京九强生物技术股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 因北京九强生物技术股份有限公司(以下简称"公司")通过集中竞价 交易方式回购的回购专用账户内的 3,544,084 股股份依法不参与 2024 年年 度利润分配，公司本次实际现金分红的总金额=实际参与分配的股本×分配 比例，即 233,913,004.00 元=584,782,510 股×0.4000000 元/股。因公司回 购股份不参与分红，本次权益分派实施后，根据股票市值不变原则，实施 权益分派前后公司总股本保持不变，现金分红总额分摊到每一股的比例将 减小，因此，本次权益分派实施后除权除息价格计算时，每股现金红利应 以 0.3975903 元/股计算。（每股现金红利=现金分红总额/总股本，即 0.3975903 元/股=233,913,004.00 元÷588,326, ...

转债代码：123150 转债简称：九强转债 证券代码：300406 证券简称：九强生物 公告编号：2025-035 北京九强生物技术股份有限公司 关于九强转债转股价格调整的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 一、转股价格调整依据 根据《北京九强生物技术股份有限公司（以下简称"公司"）创业板向不特定对 象发行可转换公司债券募集说明书》以下简称（"《募集说明书》"）相关条款的规 定，在本次可转债发行之后，当公司因派送股票股利、转增股本、增发新股（不包括 因本次可转债转股而增加的股本）、配股、派送现金股利等情况使公司股份发生变化 时，将按下述公式进行转股价格的调整（保留小数点后两位，最后一位四舍五入）： 派送股票股利或转增股本：P1=P0/(1+n)； 其中：P0 为调整前转股价，n 为送股或转增股本率，k 为增发新股或配股率，A 为 增发新股价或配股价，D 为每股派送现金股利，P1 为调整后转股价。 当公司出现上述股份和/或股东权益变化情况时，将依次进行转股价格调整，并 在深圳证券交易所网站和中国证券监督管理委员会指定的上市公司信息披 ...

证券代码：300406 证券简称：九强生物 公告编号：2025-033 转债代码：123150 转债简称：九强转债 北京九强生物技术股份有限公司 关于实施权益分派期间九强转债暂停转股的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 北京九强生物技术股份有限公司（以下简称"公司"）将于近日实施公司 2024 年 年度权益分派，根据《北京九强生物技术股份有限公司创业板向不特定对象发行可转 换公司债券募集说明书》中"转股价格的调整方式及计算公式"条款的规定（详见附件） 及有关业务办理指南的规定，自 2025 年 4 月 23 日起至 2024 年年度权益分派股权登记 日止，公司可转换公司债券（债券代码：123150；债券简称：九强转债）将暂停转股， 2024 年年度权益分派股权登记日后的第一个交易日起恢复转股。在上述暂停转股期间， 公司可转换公司债券正常交易，敬请"九强转债"债券持有人留意。 特此公告。 北京九强生物技术股份有限公司董事会 2025 年 4 月 22 日 附件：《北京九强生物技术股份有限公司创业板向不特定对象发行可转换公司债券 ...

联慧意见（2025）字第【057】号 关于北京九强生物技术股份有限公司 2024年年度股东大会 二〇二五年四月 之 法律意见书 北京联慧律师事务所 关于北京九强生物技术股份有限公司 2024年年度股东大会 之 联慧意见（2025）字第【057】号 第一部分 前 言 致：北京九强生物技术股份有限公司 北京联慧律师事务所(以下简称"本所")接受贵公司委托，指派吴姝霖律师、 张娜律师出席并见证公司2024年年度股东大会(以下简称"本次股东大会")，并 依据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共和国 证券法》(以下简称"《证券法》")、《上市公司股东大会规则》(以下简称"《股 东大会规则》")以及《北京九强生物技术股份有限公司章程》(以下简称"《公 司章程》")等有关规定，就本次股东大会的召集、召开程序、出席现场会议人员 的资格、召集人资格、会议表决程序及表决结果等事项出具本法律意见书。为出 具本法律意见书，本所律师审查了公司本次股东大会的有关文件和材料。本所律 师得到公司如下保证，即其已提供了本所律师认为出具本法律意见书所必需的材 料，所提供的原始材料、副本、复印件等材料、口头证言均符合真 ...